A Phase II Randomized Trial with a Modified Dose and Schedule of Subcutaneously Administered Azacitidine and Erythropoietin versus Azacitidine Alone in Patients with Low-Risk Myelodysplastic Syndromes (Less than 11% Marrow and Peripheral Blood Blasts)

For full description, see www.clinicaltrials.gov.

Manuscripts/Articles:

• Sayar H, Chan RJ, Orschell CM, Chan EM, Yu Z, Hood D, Plett A, Yang Z, Hui CL, Nabinger SC, Kohlbacher KJ, West ES, Walter A, Sampson C, Wu J, Cripe LD. Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group MDS04-85. Leuk Res. 2011 Aug;35(8):1108-10. doi: 10.1016/j.leukres.2011.02.025. Epub 2011 Mar 21.